OverviewSuggest Edit
MeiraGTx is a gene therapy company, which is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The Company is pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. MeiraGTx is also developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration.
| Type | Public | |
| Founded | 2015 | |
| HQ | London, GB | Map |
| Website | meiragtx.com |
Recent NewsAll News
- MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
- MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
- MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
- MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment
Key People/Management at MeiraGTx
Keith R. Harris
Chairman of the Board
Alexandria Forbes
President and Chief Executive Officer, Director
Richard Giroux
Chief Operating Officer and Chief Financial Officer
Ellen Hukkelhoven
Independent Board Member
Christine Sheehy
SVP, Global Integration
Stuart Naylor
Chief Development Officer
MeiraGTx Office Locations
MeiraGTx has offices in London, New York and Leiden
London, GB (HQ)
7NQ 92 Britannia Walk
Leiden, NL
Biopartner Gebouw 2 19 J.H. Oortweg
New York, NY, US
450 E 29th St 15th Floor
MeiraGTx Financials and Metrics
MeiraGTx Revenue
MeiraGTx's revenue was reported to be $13.29 m in FY, 2019
| USD | |
|---|---|
Revenue (Q3, 2020) | 5.1m |
Net income (Q3, 2020) | (6.4m) |
EBIT (Q3, 2020) | (8.4m) |
Market capitalization (8-Jan-2021) | 713.3m |
Closing stock price (8-Jan-2021) | 16.4 |
Cash (30-Sept-2020) | 179.1m |
MeiraGTx's current market capitalization is $713.3 m.
Annual
Annual
Annual
Quarterly
| USD | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|
Net Income | (46.4m) | (61.8m) | (18.0m) | (38.8m) | (49.3m) | (15.7m) | (41.1m) | (47.5m) |
Depreciation and Amortization | 1.0m | 1.5m | 499.6k | 1.0m | 1.6m | 815.4k | 1.8m | 2.8m |
Accounts Payable | (2.4m) | (2.3m) | 304.7k | 266.9k | 1.4m | 3.9m | (704.3k) | 480.9k |
Cash From Operating Activities | (36.4m) | (47.4m) | 82.2m | 60.4m | 42.0m | (12.4m) | (25.3m) | (34.4m) |
| USD | Q2, 2018 |
|---|---|
EV/EBIT | -8.3 x |
EV/CFO | -5.8 x |
Financial Leverage | 1.1 x |
MeiraGTx Cybersecurity Score
MeiraGTx Online and Social Media Presence
513 Twitter followers
MeiraGTx has 513 Twitter Followers. The number of followers has increased 0.4% month over month and increased 3.6% quarter over quarter
MeiraGTx's Trends
MeiraGTx News and Updates
December 16, 2020
MeiraGTx To Present Clinical Program Update for AAV-hAQP1 Treatment of Radiation-Induced Xerostomia
Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET Webcast and conference call to take place on December 17, 2020 at 8:00 a.m. ET
November 30, 2020
MeiraGTx to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
LONDON and NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Evercore ISI 3rd Annual HealthCONx Co…
November 23, 2020
MeiraGTx to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
LONDON and NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will participate in a fireside chat at the Piper Sandler …
November 13, 2020
MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment
Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months Data presented at AAO 2020 Virtual Annual Meeting show sustained improvements in retinal sensitivity at 12 months
October 03, 2020
MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)
LONDON and NEW YORK, Oct. 03, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month data from the ongoing Phase 1/2 clinical trial (NCT03252847) of AAV-RPGR, an investigational gene therapy in develop…
September 22, 2020
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting
- Nine-Month Follow-Up Data to be Presented - - Nine-Month Follow-Up Data to be Presented -
MeiraGTx Blogs
October 28, 2020
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting
12-Month Dose Escalation Data from Phase 1/2 Clinical Trial to be Presented LONDON and NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that twelve-month results from the ongoing Phase 1/2
August 05, 2020
MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer
LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Robert K. Zeldin , M.D. as chief medical officer (CMO). A clinical immunologist by training, Dr.
May 07, 2020
MeiraGTx Reports First Quarter 2020 Financial Results
LONDON and NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the first quarter ended March 31, 2020 and provided an update on recent progress.
May 06, 2020
MeiraGTx to Present at the Virtual Bank of America Securities 2020 Health Care Conference
LONDON and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Virtual Bank of America Securities
March 11, 2020
MeiraGTx Reports Full Year 2019 Financial Results
MeiraGTx Reports Full Year 2019 Financial Results
Content Import
Wed, 03/11/2020 - 17:01
MeiraGTx Reports Full Year 2019 Financial Results
March 11, 2020
This release is a backfill from a News Wire
Earnings
LONDON and NEW YORK, March 11, 2020 (GL…
March 02, 2020
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
Content Import
Mon, 03/02/2020 - 08:31
MeiraGTx Announces Priority M…
MeiraGTx Frequently Asked Questions
When was MeiraGTx founded?
MeiraGTx was founded in 2015.
Who are MeiraGTx key executives?
MeiraGTx's key executives are Keith R. Harris, Alexandria Forbes and Richard Giroux.
How many employees does MeiraGTx have?
MeiraGTx has 130 employees.
What is MeiraGTx revenue?
Latest MeiraGTx annual revenue is $13.3 m.
What is MeiraGTx revenue per employee?
Latest MeiraGTx revenue per employee is $102.2 k.
Who are MeiraGTx competitors?
Competitors of MeiraGTx include Caribou Biosciences, Editas Medicine and Evolutionary Genomics.
Where is MeiraGTx headquarters?
MeiraGTx headquarters is located at 7NQ 92 Britannia Walk, London.
Where are MeiraGTx offices?
MeiraGTx has offices in London, New York and Leiden.
How many offices does MeiraGTx have?
MeiraGTx has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies